No Cover Image

Journal article 408 views 72 downloads

Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics

Helen Yu

The Journal of Antibiotics, Volume: 74, Issue: 9, Pages: 543 - 546

Swansea University Author: Helen Yu

  • 64382.VOR.pdf

    PDF | Version of Record

    © The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (378.09KB)

Check full text

DOI (Published version): 10.1038/s41429-021-00439-w

Abstract

Failure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could...

Full description

Published in: The Journal of Antibiotics
ISSN: 0021-8820 1881-1469
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64382
first_indexed 2023-10-17T14:44:36Z
last_indexed 2024-11-25T14:13:56Z
id cronfa64382
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-10-17T15:45:31.3568367</datestamp><bib-version>v2</bib-version><id>64382</id><entry>2023-09-04</entry><title>Responsible use of negative research outcomes&#x2014;accelerating the discovery and development of new antibiotics</title><swanseaauthors><author><sid>3fa8e58607d4949e7d0d3fa8fa1c2f7d</sid><firstname>Helen</firstname><surname>Yu</surname><name>Helen Yu</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-09-04</date><deptcode>CBAE</deptcode><abstract>Failure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could be shared to prevent the vicious cycle of duplicating costly studies that produce the same negative results would greatly de-risk and accelerate the development of new antibiotics. Providing a legally supported framework that recognizes negative outcomes as intellectual contributions, which can subsequently be translated into a revenue-sharing model, may lead to more openness and value creation in support of a sustainable and responsible transformation of research into socially and economically beneficial innovations.</abstract><type>Journal Article</type><journal>The Journal of Antibiotics</journal><volume>74</volume><journalNumber>9</journalNumber><paginationStart>543</paginationStart><paginationEnd>546</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0021-8820</issnPrint><issnElectronic>1881-1469</issnElectronic><keywords>Negative research outcomes, drug discovery, drug development, antibiotic research</keywords><publishedDay>30</publishedDay><publishedMonth>9</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-09-30</publishedDate><doi>10.1038/s41429-021-00439-w</doi><url>http://dx.doi.org/10.1038/s41429-021-00439-w</url><notes/><college>COLLEGE NANME</college><department>Management School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>CBAE</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This research is supported by a grant from the Center for Digital Life Norway and the Research Council of Norway (grant agreement number 294594) and by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Program for Biomedical Innovation Law (grant agreement number NNF17SA0027784).</funders><projectreference/><lastEdited>2023-10-17T15:45:31.3568367</lastEdited><Created>2023-09-04T14:59:29.6402960</Created><path><level id="1">Faculty of Humanities and Social Sciences</level><level id="2">School of Management - Business Management</level></path><authors><author><firstname>Helen</firstname><surname>Yu</surname><order>1</order></author></authors><documents><document><filename>64382__28804__5c6de1393ead408faf8ee5b55f8b0ac8.pdf</filename><originalFilename>64382.VOR.pdf</originalFilename><uploaded>2023-10-17T15:41:48.5514114</uploaded><type>Output</type><contentLength>387166</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2023-10-17T15:45:31.3568367 v2 64382 2023-09-04 Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics 3fa8e58607d4949e7d0d3fa8fa1c2f7d Helen Yu Helen Yu true false 2023-09-04 CBAE Failure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could be shared to prevent the vicious cycle of duplicating costly studies that produce the same negative results would greatly de-risk and accelerate the development of new antibiotics. Providing a legally supported framework that recognizes negative outcomes as intellectual contributions, which can subsequently be translated into a revenue-sharing model, may lead to more openness and value creation in support of a sustainable and responsible transformation of research into socially and economically beneficial innovations. Journal Article The Journal of Antibiotics 74 9 543 546 Springer Science and Business Media LLC 0021-8820 1881-1469 Negative research outcomes, drug discovery, drug development, antibiotic research 30 9 2021 2021-09-30 10.1038/s41429-021-00439-w http://dx.doi.org/10.1038/s41429-021-00439-w COLLEGE NANME Management School COLLEGE CODE CBAE Swansea University This research is supported by a grant from the Center for Digital Life Norway and the Research Council of Norway (grant agreement number 294594) and by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Program for Biomedical Innovation Law (grant agreement number NNF17SA0027784). 2023-10-17T15:45:31.3568367 2023-09-04T14:59:29.6402960 Faculty of Humanities and Social Sciences School of Management - Business Management Helen Yu 1 64382__28804__5c6de1393ead408faf8ee5b55f8b0ac8.pdf 64382.VOR.pdf 2023-10-17T15:41:48.5514114 Output 387166 application/pdf Version of Record true © The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
spellingShingle Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
Helen Yu
title_short Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
title_full Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
title_fullStr Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
title_full_unstemmed Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
title_sort Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics
author_id_str_mv 3fa8e58607d4949e7d0d3fa8fa1c2f7d
author_id_fullname_str_mv 3fa8e58607d4949e7d0d3fa8fa1c2f7d_***_Helen Yu
author Helen Yu
author2 Helen Yu
format Journal article
container_title The Journal of Antibiotics
container_volume 74
container_issue 9
container_start_page 543
publishDate 2021
institution Swansea University
issn 0021-8820
1881-1469
doi_str_mv 10.1038/s41429-021-00439-w
publisher Springer Science and Business Media LLC
college_str Faculty of Humanities and Social Sciences
hierarchytype
hierarchy_top_id facultyofhumanitiesandsocialsciences
hierarchy_top_title Faculty of Humanities and Social Sciences
hierarchy_parent_id facultyofhumanitiesandsocialsciences
hierarchy_parent_title Faculty of Humanities and Social Sciences
department_str School of Management - Business Management{{{_:::_}}}Faculty of Humanities and Social Sciences{{{_:::_}}}School of Management - Business Management
url http://dx.doi.org/10.1038/s41429-021-00439-w
document_store_str 1
active_str 0
description Failure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could be shared to prevent the vicious cycle of duplicating costly studies that produce the same negative results would greatly de-risk and accelerate the development of new antibiotics. Providing a legally supported framework that recognizes negative outcomes as intellectual contributions, which can subsequently be translated into a revenue-sharing model, may lead to more openness and value creation in support of a sustainable and responsible transformation of research into socially and economically beneficial innovations.
published_date 2021-09-30T05:13:53Z
_version_ 1851368756642578432
score 11.089572

Similar Items